Symbia Pro.specta SPECT/CT Clinical ImagesView clinical images on this page
Clinical image review
/
Data courtesy of Baylor Scott & White Medical Center, Temple, Texas, USA.
99mTc HIDA sequential planar images demonstrating normal hepatobiliary clearance
- Sequential planar static images following 99mTc-HIDA administration for evaluation of hepatobiliary transit and gall bladder function
- Study shows normal liver function and biliary clearance
- Normal gall bladder clearance following cholecystokinin (CCK) reflects adequacy of gallbladder function
SPECT – Symbia Pro.specta
Scan acquisition: 5-minute static planar anterior view, static images at 5-minute intervals following injection, CCK administered 30 minutes post injection, 5-minute static acquisition post-CCK at 5-minute intervals for 30 minutes
Injected dose: 99mTc Mebrofenin, 4.9 mCi (181.3 MBq)
/
Findings
A routine 68Ga-PSMA-11 PET/CT was performed to qualify the patient for 177Lu-PSMA-617 treatment. PET/CT findings confirmed PSMA expression in the tumors. The patient was administered with 3.76 mCi (139.12 MBq) intravenous (IV) injection of 68Ga-PSMA-11, and approximately 1 hour later, a single-scan, whole-body acquisition was conducted on Biograph mCT Flow™ PET/CT.
/
Figure 1: Coronal CT, 68Ga-PSMA-11 PET, and PET/CT images confirm PSMA expression in metastatic disease and qualify the patient for 177Lu-PSMA-617 treatment.
/
/
Figure 4: Sagittal CT through the thoracic and lumbar spine shows extensive sclerosis in the vertebral bodies reflecting metastatic disease with particularly dense sclerosis in the T5 vertebral body. Cycle 2 image shows significant decrease in mid-thoracic vertebral uptake compared to that of low thoracic and lumbar vertebrae, which can be explained by additional mid-thoracic external beam radiation delivered throughout the 177Lu-PSMA therapy regimen. Cycle 3 images acquired 7 days post injection demonstrate lower bladder uptake when increasing time lapse post injection. High uptake in the lower thoracic and lumbar vertebrae is visualized after cycles 2 and 3 but shows considerable decrease after cycles 4 and 6, which clearly demonstrates tumor response.
/
As observed in Figures 4 and 5, the SPECT/CT with xSPECT Quant images demonstrate a normal biodistribution of 177Lu-PSMA-617 and foci of increased uptake compatible with the expected distribution of targeted PSMA in concordance with findings from the preceding PSMA PET (Figures 1 and 2).